Zscaler Faces Valuation Reset as Organic Growth Falters Below Priced-In Expectations

The recent wave of price target cuts is less a verdict on Zscaler alone and more a market-driven reset for the entire cybersecurity sector. This is a classic case of expectations being priced in, followed by a reset as broader valuation pressures set in.

The catalyst was Oppenheimer's move on March 10, which lowered its price target from $280 to $250 while maintaining an "outperform" rating. The firm explicitly cited broader valuation pressures across the cybersecurity sector as the reason, noting that the adjustment reflects prevailing industry multiples. This wasn't a downgrade of the company's fundamentals, but a recalibration of its fair value within a tougher market environment.

That move was quickly joined by others, creating a consistent negative tone. Just days later, Goldman Sachs dropped its target from $290 to $257 and shifted to a "neutral" rating. Mizuho and KeyCorp also cut their targets to $250, while other firms like UBS and Sanford C. Bernstein made adjustments. The pattern is clear: multiple analysts are aligning their valuations downward in step.

The stock's reaction illustrated the "sell the news" dynamic perfectly. Even with Oppenheimer's positive rating intact, the news of the cut triggered a 3.1% drop in shares. This shows that for the market, the expectation was for a hold or even an upgrade. A reduction, however justified by sector-wide factors, was still a disappointment relative to the whisper number. The core question now is what expectations are priced in after this reset. The sector's multiples have compressed, and Zscaler's growth story must now compete against a lower valuation baseline.

The Q2 Print: Strong Headlines vs. Organic Growth Concerns

The fiscal second quarter report delivered strong headline numbers that met consensus, but the details revealed a growth story that was not accelerating fast enough for a market pricing in hyper-growth. Revenue grew 26% year over year to $815.8 million.

Annual recurring revenue (ARR) climbed 25% to $3.359 billion. On paper, this was a beat. The real disappointment was in the quality of that growth.

Investors were looking for signs that the core business was gaining steam, but the metrics for organic expansion were muted. When you strip out the contribution from the Red Canary acquisition, ARR growth slowed to 21%. More telling was the net new ARR growth, which excluding Red Canary's impact was just 7%. This is the key metric for assessing underlying demand and sales execution.

The implication is clear: the company's reported growth was being propped up by acquisition integration, not a powerful organic ramp. For a stock trading at a premium, this kind of "sandbagging" of organic metrics disappointed. The market had likely priced in faster acceleration, and the Q2 print showed the engine wasn't revving higher. This gap between headline beats and weak organic growth is a classic driver of a valuation reset, feeding the sector-wide pressure that analysts are now reflecting in their targets.

The Valuation Gap: What's Priced In vs. What's Possible

The recent sell-off has created a wide gap between the current price and the consensus view, but the market's verdict on Zscaler's future growth is the critical factor. The stock now trades around $151.61, which implies a significant discount to the median analyst price target of $250. On the surface, this suggests potential upside if the company can resume its growth trajectory. Yet the stock's performance tells a more nuanced story of faded sentiment.

Over the past year, the stock has seen a decline of 20.03% in total shareholder return, and year-to-date, it is down 31.26%. This contrasts sharply with a 3-year total shareholder return of 40.21%, highlighting that the recent weakness is a reset from a much stronger multi-year period. The market's patience for premium valuations has clearly worn thin.

The core risk is that the market has correctly priced in a new, lower growth trajectory. The expectation gap identified in the Q2 report-where strong headlines masked muted organic expansion-is now the baseline. The stock's sensitivity to any further guidance cuts underscores this vulnerability. With the P/S ratio still elevated at 8.1x, the valuation remains a function of future growth assumptions, not current cash flows. If the organic growth engine fails to accelerate, the stock could remain under pressure despite the apparent discount to analyst targets.

The bottom line is that the recent weakness is a warning sign, not a buying opportunity. The market has reset expectations, and the stock's path now depends on management delivering on a more modest growth story. For now, the valuation gap reflects not undervaluation, but a market that has already priced in a lower bar.

Catalysts and Risks: The Path to a New Equilibrium

The expectation gap is now the central narrative. The market has reset its baseline, and the stock's path hinges on whether Zscaler can close that gap positively or if further disappointments will widen it. The near-term catalysts and risks will determine if the reset is a temporary dip or the start of a new, lower equilibrium.

The next major test arrives in May with the fiscal third-quarter report. Investors will be scrutinizing the organic growth engine more closely than ever. The Q2 print showed net new ARR growth of just 7% when excluding the Red Canary acquisition's impact-a figure that signaled muted underlying demand. The market will demand to see acceleration beyond that level. Any further deceleration would confirm fears of a growth plateau, likely triggering another round of valuation compression. Conversely, a clear uptick in that organic metric would be the clearest signal that the core business is regaining momentum, potentially re-rating the growth story.

A persistent headwind is the pattern of insider selling. Over the last 90 days, insiders have sold approximately 19,350 shares. While this is a relatively small fraction of the total float, the fact that it has been a steady stream of sales-no purchases in the past six months-can erode sentiment. When those closest to the company are consistently taking money off the table, it can signal a lack of conviction in the near-term outlook, acting as a subtle but steady weight on the stock.

On the flip side, a potential positive catalyst lies in the execution of new initiatives. The company's Agentic Exchange initiative and recent enhancements to its data sovereignty platform represent attempts to re-accelerate growth and diversify its revenue base. If these new products drive faster adoption and contribute meaningfully to ARR in the coming quarters, they could provide the narrative shift needed to justify a higher multiple. Success here would be a direct challenge to the "priced-in" lower growth thesis.

The bottom line is that the stock is now a game of forward-looking conviction. The recent price target cuts reflect a market that has already priced in a more modest growth trajectory. The path to a new equilibrium depends on management delivering organic growth that exceeds that reset baseline, while navigating the subtle negative signal from insider sales and proving that new initiatives can drive the next leg of expansion.